Skip to main content
. 2014 Jul 10;4(7):e004843. doi: 10.1136/bmjopen-2014-004843

Table 3.

Other prognostic factors associated with mortality in patients with pulmonary hypertension associated with left heart disease

Factor Number of studies reporting
Number of studies in which the factor was associated with poor outcome
overall Studies based on DE Studies of PH based on DE Studies of PH based on RHC
Age 14 11 11 3
Sex (male vs female) 11 9 3 0
Racial/ethnic group 2 2 0 0
HF episodes 5 5 2 0
Prior hypertension 5 5 1 0
History of diabetes 8 8 3 0
Smoking 3 3 0 0
History of cardiovascular disease 1 1 1 0
Functional class (NYHA/WHO) 12 9 5 2
Killip class for MI 2 2 2 0
Heart rate 2 2 0 0
Systolic BP 4 4 2 0
Diastolic BP 1 1 1 0
Mean BP 1 1 1 0
SPO2 3 3 1 0
Hypotension 1 1 1 0
Atrial fibrillation 5 5 5 0
Ischaemic aetiology of HF 4 4 0 0
Urea 2 2 1 0
Kidney disease (by creatinine, GFR or haemodialysis) 17 14 6 0
BNP 3 3 2 0
Haemoglobin 2 2 0 0
Presence of COPD 4 3 3 0
Use of medications (ACEI and or beta blockers or spironolactone) 6 6 3 0
LVEF 10 10 6 NA
LV end-diastolic diameter/index 6 6 3 NA
Atrial diameter 1 1 1 NA
Deceleration time 1 1 0 NA
RV function (by TAPSE or other means) 3 3 3 NA
Functional mitral regurgitation 5 5 4 NA
RVSP ≥50 or >60 mm Hg 9 9 5 NA
End diastolic pulmonary regurgitation 1 1 1 NA

ACEI, ACE inhibitors; BNP, brain natriuretic peptide; BP, blood pressure; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; RHC, right heart catheterisation; RVSP, right ventricular systolic pressure; RV, right ventricle; TAPSE, tricuspid annular plan systolic excursion.